2,726 research outputs found
Interview with Jacqueline DeGroot
No full textJacqueline DeGroot, author of Climax and Worth Any Price, discusses how she came to be a writer, her writing process and sources of inspiration, and her experiences with self-publishing
Jacqueline Woodson: 2023 Irma Black Award Silver Medal Acceptance Speech
No full textAuthor Jacqueline Woodson gives an acceptance speech for The World Belonged to Us, illustrated by Leo Espinosa (Penguin)https://educate.bankstreet.edu/irma_black_awards/1011/thumbnail.jp
36. Weber (Heinz-Otto). Die Bedeutung und Bewertung der Pleonexie von Homer bis Isokrates
No full textDe Romilly Jacqueline. 36. Weber (Heinz-Otto). Die Bedeutung und Bewertung der Pleonexie von Homer bis Isokrates. In: Revue des Études Grecques, tome 81, fascicule 384-385, Janvier-juin 1968. pp. 253-254
Leslie Behm interviews essayist and fantasy writer Jacqueline Carey
No full textEssayist and fantasy writer Jacqueline Carey talks about the meaning of the title of her Kushiel Trilogy, how she became an author, her work in progress. She also gives advice to aspiring authors. Carey is interviewed by Michigan State University librarian Leslie Behm. Part of the MSU Libraries' Michigan Writers Series. Held in the MSU Main Library
Recommended from our members
Jacqueline Barnitz: 40 Years of Publications
No full textJacqueline Barnitz: 40 Years of Publications
Jacqueline Barnitz is responsible for establishing modern Latin American art as an area of concentration
within art history at the University of Texas at Austin, where she has taught now for 25 years. She's a
major reason why UT Austin is known as the best place in the nation for studying modern Latin American
art. A notable record of publication accompanies her career as a distinguished educator. In fact, her
interest in Latin American art goes back to her tenure as an art critic in New York for the periodicals Art
Voices (1964-1965) and Arts Magazine (1964-1975). Additionally, she's been the curator of numerous art
exhibitions and, subsequently, the author of many exhibition catalogs. In 2000 UT Press published her
much-anticipated and seminal book Twentieth-Century Art of Latin America, which quickly became the
textbook on the subject. We present this display of selected publications as a tribute to her outstanding
contributions to the university and to the field of art history.UT Librarie
Une visite au théâtre / Jacqueline Margueritte, réal. ; Marie-José Weber, Françoise Fabrice, aut.
No full textCollection : Expression françaiseRésumé : Découverte en caméra subjective du théâtre Sarah Bernhardt (actuel Théâtre de la Ville) où se joue 'La calèche' de Jean Giono. La caméra explore le théâtre et ses coulisses vides avec en son off les ambiances de vie du théâtre (source : Média Scérén)Durée : 00:23:45Thème : Arts du spectacl
First person – Jacqueline Weidner
No full textFirst Person is a series of interviews with the first authors of a selection of papers published in Biology Open (BiO), helping early-career researchers promote themselves alongside their papers. Jacqueline Weidner is first author on ‘Hormones as adaptive control systems in juvenile fish’, published in BiO. Jacqueline conducted the research described in this article while a PhD student at the University of Bergen, Norway. She is now an assistant professor at the Western Norway University of Applied Sciences, Norway, investigating sexual selection and modelling of evolutionary patterns
Jacqueline Rubellin-Devichi, Brigitte Trillat (présent.) et al, Le droit. 1. Fondements et pratiques, 1988
No full textJacqueline Rubellin-Devichi, Brigitte Trillat (présent.) et al, Le droit. 1. Fondements et pratiques, 1988. In: Droit et société, n°9, 1988. Max Weber. Réception, diffusion de sa sociologie du droit. pp. 330-331
Jacqueline Rubellin-Devichi (Dir.), Droit du logement et stratégies familiales/Centre du Droit de la Famille, 1988
No full textFontaine Monique. Jacqueline Rubellin-Devichi (Dir.), Droit du logement et stratégies familiales/Centre du Droit de la Famille, 1988. In: Droit et société, n°9, 1988. Max Weber. Réception, diffusion de sa sociologie du droit. p. 325
Balancing Potential Benefits and Risks of Bruton Tyrosine Kinase Inhibitor Therapies in Multiple Sclerosis During the COVID-19 Pandemic
No full textBruton tyrosine kinase inhibitors (BTKis) encompass a new class of therapeutics currently being evaluated for the treatment of multiple sclerosis (MS). Whether BTKis affect COVID-19 risk or severity or reduce vaccine efficacy are important but unanswered questions. Here, we provide an overview on BTKi mechanisms relevant to COVID-19 infection and vaccination and review preliminary data on BTKi use in patients with COVID-19. BTKis block B-cell receptor– and myeloid fragment crystallizable receptor–mediated signaling, thereby dampening B-cell activation, antibody class-switching, expansion, and cytokine production. Beyond antibodies, COVID-19 severity and vaccine efficacy appear largely linked to T-cell responses and interferon induction, processes not directly affected by BTKis. Given that B cells have clear roles in antigen presentation to T cells, however, it is possible that BTKis may indirectly interfere with beneficial or detrimental T-cell responses during COVID-19 infection or vaccination. In addition to these possible effects on generating a protective immune response, BTKis may attenuate the hyperinflammatory dysregulation often seen in severe cases of COVID-19 that evolves as a key risk factor in this disease. Currently available outcomes from BTKi-treated patients with COVID-19 are discussed. Clinical trials are currently underway to evaluate the safety and efficacy of BTKis in individuals with MS. Although limited data suggest a potential benefit of BTKis on outcomes for some COVID-19 patients, data from adequately powered, prospective and randomized clinical trials are lacking. Likewise, the specific effect of BTKis on the safety and efficacy of COVID-19 vaccines remains to be determined. Any potential unknown risks that BTKi therapy may present to the patient relative to COVID-19 infection, severity, and vaccine efficacy must be balanced with the importance of timely intervention to prevent or minimize MS progression.Bruton tyrosine kinase inhibitors (BTKis) encompass a new class of therapeutics currently being evaluated for the treatment of multiple sclerosis (MS). Whether BTKis affect COVID-19 risk or severity or reduce vaccine efficacy are important but unanswered questions. Here, we provide an overview on BTKi mechanisms relevant to COVID-19 infection and vaccination and review preliminary data on BTKi use in patients with COVID-19. BTKis block B-cell receptor– and myeloid fragment crystallizable receptor–mediated signaling, thereby dampening B-cell activation, antibody class-switching, expansion, and cytokine production. Beyond antibodies, COVID-19 severity and vaccine efficacy appear largely linked to T-cell responses and interferon induction, processes not directly affected by BTKis. Given that B cells have clear roles in antigen presentation to T cells, however, it is possible that BTKis may indirectly interfere with beneficial or detrimental T-cell responses during COVID-19 infection or vaccination. In addition to these possible effects on generating a protective immune response, BTKis may attenuate the hyperinflammatory dysregulation often seen in severe cases of COVID-19 that evolves as a key risk factor in this disease. Currently available outcomes from BTKi-treated patients with COVID-19 are discussed. Clinical trials are currently underway to evaluate the safety and efficacy of BTKis in individuals with MS. Although limited data suggest a potential benefit of BTKis on outcomes for some COVID-19 patients, data from adequately powered, prospective and randomized clinical trials are lacking. Likewise, the specific effect of BTKis on the safety and efficacy of COVID-19 vaccines remains to be determined. Any potential unknown risks that BTKi therapy may present to the patient relative to COVID-19 infection, severity, and vaccine efficacy must be balanced with the importance of timely intervention to prevent or minimize MS progression
- …
